Chris Abbosh
YOU?
Author Swipe
View article: Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment Open
PURPOSE Quantifying changes in circulating tumor DNA (ctDNA) during treatment can rapidly identify patients responding to therapy, but accurate interpretation requires an understanding of variability in ctDNA levels in the absence of treat…
View article: Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer
Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer Open
Our findings suggest preoperative ctDNA detection in patients with resectable clinical stage I NSCLC using MCED, a pan-cancer screening test developed for use in an asymptomatic population, has no detectable prognostic value for relapse ≤5…
View article: Next-generation MRD assays: do we have the tools to evaluate them properly?
Next-generation MRD assays: do we have the tools to evaluate them properly? Open
Circulating tumour DNA (ctDNA) detection of molecular residual disease (MRD) in solid tumours correlates strongly with patient outcomes and is being adopted as a new clinical standard. ctDNA levels are known to correlate with tumor volume,…
View article: Non-Small-Cell Lung Cancer Promotion by Air Pollutants
Non-Small-Cell Lung Cancer Promotion by Air Pollutants Open
Environmental carcinogenic exposures are major contributors to global disease burden yet how they promote cancer is unclear. Over 70 years ago, the concept of tumour promoting agents driving latent clones to expand was first proposed. In s…
View article: Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay Open
Sequencing of cell-free DNA (cfDNA) in cancer patients’ plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection decreases at l…
View article: Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma Open
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therap…
View article: Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibition
Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibition Open
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumour cell intrinsic and microenvironmental features underpinning CPI sensitization. Here we collated whole-exome …
View article: Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology
Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology Open
Salivary gland-like and dermal analogue tumours of the breast are rare lesions that can be diagnostically challenging for pathologists. Data on the clinical behaviour and molecular characterisation of these mammary tumours are limited and …